Abstract

There is steady rise in the number of immunocompromised population due to increased use of potent immunosuppression therapies. This is associated with increased risk of acquiring fungal opportunistic infections in immunocompromised patients which account for high morbidity and mortality rates, if left untreated. The conventional antifungal drugs to treat fungal diseases (mycoses) are increasingly becoming inadequate due to observed varied susceptibility of fungi and their recurrent resistance. RNA interference (RNAi), sequence-specific gene silencing, is emerging as a promising new therapeutic approach. This chapter discusses various aspects of RNAi, viz., the fundamental RNAi machinery present in fungi, in silico siRNA features, designing guidelines and tools, siRNA delivery, and validation of gene knockdown for therapeutics against mycoses. Target gene identification is a crucial step in designing of gene-specific siRNA in addition to efficient delivery strategies to bring about effective inhibition of fungi. Subsequently, designed siRNA can be delivered effectively in vitro either by soaking fungi with siRNA or by transforming inverted repeat transgene containing plasmid into fungi, which ultimately generates siRNA(s). Finally, fungal inhibition can be verified at the RNA and protein levels by blotting techniques, fluorescence imaging, and biochemical assays. Despite challenges, several such in vitro studies have spawned optimism around RNAi as a revolutionary new class of therapeutics against mycoses. But, pharmacokinetic parameters need to be evaluated from in vivo studies and clinical trials to recognize RNAi as a novel treatment approach for mycoses.

C. K. Jain (✉)
Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India

G. Wadhwa
Department of Biotechnology, Apex Bioinformatics Centre, Ministry of Science & Technology, New Delhi, India

© Springer Nature Singapore Pte Ltd. 2018
G. Wadhwa et al. (eds.), Current trends in Bioinformatics: An Insight,
https://doi.org/10.1007/978-981-10-7483-7_12
12.1 Introduction

The last two decades have seen a rising trend in the immunocompromised patients (Richardson 1991; Krcmery 1996; Warnock and Richardson 1991; Ribes et al. 2000), who are at a heightened risk for “opportunistic” fungal infections (mycoses). The fungal infections can affect any part of the body and cause superficial mycoses (affecting only the outermost layers of the skin and hair), cutaneous mycoses (extending deeper into the layers of the skin, hair, and nail), subcutaneous mycoses (involve the dermis, subcutaneous tissues, muscle, and fascia), or systemic mycoses (dissemination in the body). The fungal diseases (listed in Table 12.1) are classified according to the three important phyla of the fungal taxonomy – Ascomycetes, Basidiomycetes, and Zygomycetes. These diseases turn out to be severe if disseminated, which is common in the immunosuppressed. Candidiasis is one of the highly frequent fungal infections in 90% of untreated, advanced HIV cases suffering from oropharyngeal candidiasis according to World Health Organization (WHO) 2010 statistics. Another study reported overall mortality rate of approximately 80% for zygomycosis (Ribes et al. 2000) and 80–90% in invasive aspergillosis of high-risk leukemia patients and allogeneic bone marrow transplant patients (Chamilos and Kontoyiannis 2005).

The existing fungal treatments require parallel approaches involving surgical intervention and antifungal therapy (Ribes et al. 2000). Surgical intervention has shown improving survival rates for many patients, but surgery is not the only solution in treating fungal diseases. The currently available antifungal drugs comprise polyenes, macrolides, azole drugs, and echinocandins (Mukherjee et al. 2005). Among them, the polyene amphotericin B is the first-line drug of choice for invasive mycoses (Ribes et al. 2000). These drugs have drawbacks such as nephrotoxicity and hepatotoxicity as exhibited by liposomal amphotericin B, narrow spectrum of activity as shown by fluconazole, and itraconazole causes problems with absorption (Pauw and Picazo 2008). Moreover, the fungi are acquiring resistance recurrently against novel antifungal agents (Rogers 2008) either due to defects in drug import and efflux of drugs, variations in intracellular drug processing, alterations in the enzymes of a target-specific biosynthetic pathway, or its competitive inhibition (Chamilos and Kontoyiannis 2005; Bhanderi et al. 2009).

The existing treatments are not effective due to varied susceptibility of fungi toward the drugs; hence, newer safe and effective therapeutic interventions are desired. There have been reports of the use of gene therapy, antisense oligonucleotides, ribozymes, DNAzymes, and RNAi therapy. RNAi scores several
Table 12.1  Fungal diseases associated with immunocompromised patients

| Disease          | Causal fungal agent               | Symptoms                                                                 | Treatment                              |
|------------------|-----------------------------------|--------------------------------------------------------------------------|----------------------------------------|
| **Ascomycetes**  |                                   |                                                                          |                                        |
| Candidiasis      | *Candida albicans, C. tropicalis* | Localized infection of the skin or mucosal membranes like the vagina: itching, burning, soreness, irritation, and a whitish discharge | Clotrimazole, nystatin, amphotericin B, fluconazole, caspofungins |
| Aspergillosis    | *Aspergillus fumigatus* (causes more than 95% of cases), *A. flavus* | Fungus balls in lungs, coughing up blood; fever, chest pain, difficulty breathing; aspergillosis of the ear canal causes itching and occasionally pain and fluid draining | Amphotericin B, voriconazole, caspofungin |
| Histoplasmosis   | *Histoplasma capsulatum, H.duboisii* (causes disease restricted to Africa and Madagascar) | Acute respiratory infection leads to respiratory symptoms, malaise, fever, chest pains, dry cough, flu-like illness, fever, cough, headache | Fluconazole, itraconazole, amphotericin B |
| Coccidioidomycosis | *Coccidioides immitis* | Only 40% cases symptomatic, flu-like symptoms, fever, cough, headache, rash, myalgia, chest pain, fatigue, arthralgia | Fluconazole, amphotericin B, voriconazole, posaconazole |
| Blastomycosis    | *Blastomyces dermatitidis*        | Fever, chills, myalgia, arthralgia, pleuritic chest pain, cough, difficulty breathing can become disseminated to mostly skin, bones, and genitourinary tract | Amphotericin B, itraconazole, voriconazole |
| Penicilliosis    | *Penicillium marneffei*           | Fever, weight loss, anemia, pneumonitis, skin lesions, pharyngeal, and palatal lesions | Amphotericin B, itraconazole |
| **Basidiomycetes** |                                   |                                                                          |                                        |
| Cryptococcosis   | *Cryptococcus neoformans, C.grubii* | Headache, fever, visual loss, osteolytic bony lesions, meningitis, calcification in lungs | Fluconazole, amphotericin B |

(continued)
benefits over other techniques, for instance, its effective delivery into various organs at low concentrations, thereby increasing safety, its cost-effectiveness as compared to protein/enzymes, and its non-immunogenicity bypassing the interferon pathway (Ruddon 2007). Subsequently, it was marked the “Breakthrough of the Year” in 2002 by Science magazine. One of the recent developments in this field has been the FDA approval of siRNA (short interfering RNA) drug DGFi in 2008, developed by Quark Pharmaceuticals, Inc., for use in kidney transplantation. Another siRNA-based therapy, Sirna-027 originally developed by Sirna Therapeutics for the treatment of acute macular degeneration, is moving forward into phase II clinical trials. Hence, the vital relevance of innovative treatments like the siRNA therapy can be envisaged for antifungal infections. RNAi application has also been identified in functional genomics and therapeutics, viz., cancer, neurodegenerative diseases, and multiple sclerosis besides fungal infection. This chapter presents the prospects of RNAi technology in fungal infection.

### 12.2 RNA Interference in Fungi

Gene cosuppression (RNAi-type phenomenon), which is more commonly known as “quelling” in fungi, was first discovered in the filamentous fungus *Neurospora crassa* by Romano and Macino (1992). The significant aspect of RNAi was established in 1998 when Fire and Mello found out that dsRNA is 10–100 times more effective in triggering silencing as compared to ssRNA in *Caenorhabditis elegans* (Fire et al. 1998) for which they shared the Nobel Prize in Medicine and Physiology in 2006.

RNAi naturally occurring “sequence-specific gene silencing” phenomenon and evolutionarily highly conserved mechanism are well developed in eukaryotic organisms, which is induced by double-stranded small noncoding RNA (dsRNA). These RNA-mediated gene silencing pathways have been comparatively thoroughly known and established in plant and animal system and are widely investigated in a variety of fungi, few of them are reported on opportunistic

| Disease                  | Causal fungal agent                                                                 | Symptoms                                                                                     | Treatment                        |
|--------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------|
| Zygomycetes              | *Rhizopus oryzae*, *R. rhizopodiformis*, *Rhizomucor pusillus*, *Absidia corymbifera*, *Apophysomyces elegans*, *Mucor circinelloides* | Facial pain, headache, nausea, fever, blood or pus draining from nose, lethargy, impaired vision, bulging eyes, convulsions, ulcers in roof of mouth, may become disseminated | Amphotericin B, posaconazole  |

Table 12.1 (continued)
pathogenic fungi in human. The RNAi machinery in fungi shares similar mechanistic principles with other organisms where RNAi has been discovered which consists of dsRNA precursors, Dicer enzyme, RISC (RNA-induced silencing complex), and the target mRNA. The dsRNA is processed into short interfering RNA (siRNA) by two steps – the initiator step and the effector step. In the *initiator step*, the dsRNA is cleaved by the enzyme Dicer of the RNase III family (Jinek and Doudna 2009) into specific lengths of 21–25 nucleotides. In the *effector step*, the siRNA must segregate into “competent” single strands (the guide strands) which are guided through a ribonucleotide protein complex called the RISC (Siomi and Siomi 2009), a member of the Argonaute family of proteins (Song et al. 2004a, b; Leuschner et al. 2006; Fulci and Macino 2007). Both Dicer and RISC complex require ATP for energy. The Argonaute has a N-terminal domain, PAZ domain, a middle domain, and a PIWI domain. It is the “guide strand” which is incorporated into RISC; the non-incorporated strand known as the “passenger strand” is also crucial for proper target mRNA cleavage. Until the passenger strand is not cleaved at ten nucleotides from the 5′ phosphate of the guide strand, target mRNA cleavage is severely impaired (Leuschner et al. 2006). The cleaved target mRNA is utilized by RNA-dependent RNA polymerase (RdRp) generating more dsRNA that is further recognized and cleaved by Dicer to increase the number of siRNA molecules (Scheipers 2005). Genes responsible for RNAi have been discovered in fungi such as qde-1 (quelling deficient-1) which was the first RNAi gene discovered in *N. crassa* which encodes a cellular RdRp. Simultaneously, qde-2 was cloned and found out to encode Argonaute protein. Further, partially redundant Dicer proteins DCL-1 (Dicer-like-1) and DCL-2 have been characterized from *N. crassa* by reverse genetics (Li et al. 2010).

So far, RNAi mechanism has not been observed in *Saccharomyces cerevisiae*, *Candida guilliermondii*, *C. lusitaniae*, *C. tropicalis*, and *Ustilago maydis* (Nakayashiki 2005; Münsterkötter and Mannhaupt 2008). In *S.cerevisiae*, it has been attributed to the absence of conserved components like Dicer-like RNases, Argonaute or PIWI-like components, and RNA-dependent RNA polymerases. However, RNAi was very recently discovered in *S. castellii*, which is closely related to *S.cerevisiae*, and also in *C. albicans*, a common human pathogen, by David P. Bartel’s lab [22] (Drinnenberg et al. 2009). They found out that these species with noncanonical Dicer activity have RNase III domain containing gene to generate siRNA(s). This gene is orthologous to RNase III domains of other Argonaute-containing budding yeasts and is mostly enriched in long inverted repeats and transposable elements.

### 12.3 siRNA Design and Computational Tools

A significant facet of siRNA design involves identification and characterization of gene target which plays a key role in the survival of the organism such that suppression of the gene by inhibiting translation should limit the growth of the fungus. A particular fungal disease is often caused by more than one fungus, for
instance, zygomycosis is caused by *Rhizopus, Absidia, Mucor*, and *Rhizomucor*. siRNA can be designed taking into consideration a conserved antifungal drug target present ubiquitously in the species, so that the drug discovery process becomes less intricate; but a crucial point to be taken care of is that the protein and its corresponding gene should not have similarities with the human genome, such that the human processes are not affected. For instance, cell wall is a very promising target in disease-causing fungi. The pathway for formation of cell wall is readily accessible (Moussian 2008), and the KEGG database (http://www.genome.jp/kegg/) can be referred. Silencing a gene coding for a significant component of the cell wall biosynthesis pathway can delimit the formation of cell wall and hence restrain the growth of the pathogenic fungus. For instance, a study reported loss of a cell wall polysaccharide, $\alpha$-(1,3) glucan synthase from the cell walls of *Histoplasma capsulatum* which led to decreased virulence and pathogenesis of the fungi (Rappleye et al. 2004). Apart from the cell wall, targeting can be carried out against lipid biosynthesis pathways or at the translational or posttranslational levels. Previous studies have led to the confirmation of N-myristoyl transferase, lanosterol 14-$\alpha$ demethylase, and geranylgeranyl transferase I as potential drug targets against which antifungal drugs benzofurans, azoles, and azaphilones have been designed, respectively (Kawasaki et al. 2003; Song et al. 2004; Singh et al. 2005). Furthermore, orthologous and paralogous studies can be performed to check the presence of the target gene in other related organisms, which can highlight the evolutionary history of the gene, and information about gene conservation can acquaint us with the vital relevance of the gene.

siRNA should be a perfect complementary match to its target mRNA, and hence, it needs to be cautiously designed. Various computational tools are freely available online for designing siRNA. For instance, the Ambion’s siRNA Target Finder, Eurofins MWG Operon’s free online siMAX™ Design Tool, the BLOCK-iT™ RNAi Designer from Invitrogen, the SVM RNAi 3.6, and the siDESIGN Center by Dharmacon can be used for siRNA designing against fungal genes. The designing of siRNA molecule is purely dependent on suitable selection of various siRNA features, viz., sequence, motif, GC content, and thermodynamic features, etc. Moreover, various studies have documented the comparison among few siRNA design tools (Yiu et al. 2005; Matveeva et al. 2007). The tools mainly follow the Reynolds et al. (2004) or Tuschl et al. (1999) guidelines for rational siRNA design of usually 21 nucleotides in length. Few guidelines are described in onward section. According to these guidelines, regions within 50–100 bp of the start codon and the termination codon; intronic regions, stretches of 4 or more bases such as AAAA and CCC; and regions with GC content less than 30% or more than 60%, single-nucleotide polymorphisms, repeats, and low complex sequences should be avoided.

12.3.1 General Guidelines for siRNA Designing

Many guidelines to design siRNA were proposed by different groups which are mentioned below.
12.3.1.1 MPI (Max-Planck-Institute) Rule Set
Tuschl et al. (1999) have provided a set of guidelines (commonly known as the MPI principles) on how to design effective siRNA.

Initially an empirical rules (based on GC content and symmetric 3' TT overhangs) for effective siRNA designing were established by Tuschi et al. (1999), which have been found to show significant proportion of ineffective siRNAs as described by Yiu et al. (2005) and identify the need of understanding the structural features of sequences (Yiu et al. 2005). Therefore, the new rules were suggested with advancement of technology for effective designing of siRNA, (1) where select targeted region from a given cDNA sequence beginning 50–100 nt. downstream of start codon (2) afterward finds 23-nt sequence motif AA (N<sub>19</sub>). If no suitable sequence is found, then find for 23-nt sequence motif NA(N<sub>21</sub>) and convert the 3' end of the sense siRNA to TT or search for [N (any nucleotide base pair)A (adenine) R (adenine or guanine (purines)) (N<sub>17</sub>)Y(thymine or cytosine (pyrimidines)) NN], and the GC content must be around 50% in target sequence.

12.3.1.2 Rational siRNA Design
In the designing of efficient siRNA molecule, a rational rule sets (total of eight criteria with weight values) were developed after the experiential analysis of the silencing efficiency of 180 siRNAs targeting the mRNA of two genes, by Reynolds et al. (2004) at Dharmacon, Inc.; these rules/criteria cover the different compositional properties such as sequential features of individual siRNAs. These characteristics are used by rational siRNA design algorithm to evaluate potential targeted sequences and assign scores to them (Reynolds et al. 2004). The higher value or score of these sequences reflects the higher chance of success of RNAi experiment.

The tools offered by Dharmacon, Inc. deploy the eight criteria-based (rational siRNA design rules) guideline, while Maurice Ho et al. have developed the Excel-based template on similar guidelines and available at http://boz094.ust.hk/RNAi/siRNA.

It is clear from Fig. 12.1 that different base pair shows differential stability with respect to their position (H = A, C or U).

12.3.1.3 Challenges
Despite several in silico siRNA design cases being reported in fungal systems, there are challenges that need to be addressed. These include optimal siRNA designing, off targeting, and efficient delivery systems apart from the genomic architecture and levels of organizational complexity. For example, whole-genome duplication events are commonly observed in fungi (Wapinski et al. 2007; Dujon et al. 2004; Ibrahim et al. 2009) such as in Rhizopus oryzae, giving rise to paralogous genes might not have 100% nucleotide sequence similarity with each other, which are actively expressed to code for an enzyme. Such constraints are often envisaged while designing effective siRNA against a fungal enzyme, as targeting only one out of many genes for a given enzyme target doesn’t result in a very high efficacy for
silencing (Yamada et al. 2007) silenced only one out of the three α-amylase genes in Aspergillus oryzae and found merely 10% silencing, which is not sufficient to enter the therapeutic phase. Hence, designing common siRNA for all the genes targeting an enzyme becomes a very arduous task. Chitin synthase is a well-accepted antifungal drug target, yet it cannot be used to design siRNA(s) for R. oryzae because genome level analysis has revealed that 23 genes can encode chitin synthase (Ibrahim et al. 2009). The prospects of selecting the conserved regions of an enzyme are lucrative, as a single siRNA might be effective against several fungi causing a particular disease, but the enzyme should be present exclusively in fungi. Hence, target selection is critical toward its gene nature and diversity.

12.3.1.4 Resources and Tools
There are several tools available to design the siRNA, few of them are described in Table 12.2.

siVirus It is an effective siRNA designing tool for several divergent viral genomes such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza virus, and SARS coronavirus, based on various siRNA designing guidelines such as Ui-Tei et al. (2004), Reynolds et al. (2004), and Amarzguioui and Prydz (2004), while the off-targeting siRNA sequences were identified using siDirect tool. Out of 35 predicted siRNAs, 31 sequences of siRNA against conserved region of HIV-1 genome have shown inhibition of viral replication, which conclusively supports the designing capacity of these tools (Naito et al. 2006).

RNA Rule Set 1.0 It is a Java-based program to predict the efficient siRNA design. Basically siRNArules 1.0 operates with two scoring sums: one for the positive rules deduced from the set of the best siRNAs and one for the negative rules deduced from the set of the worst siRNAs. The rank is calculated by a simple sum of these two values. How these rules should be weighted to obtain the most efficient algorithm is a challenge for the open-source community (Holen 2006).

DSIR This tool was developed by Vert et al. (2006) which uses only two parameters for designing of siRNA, i.e., position-specific thermodynamic stability and non-position-specific motif formation. Their composite score decides which
siRNA is better through lasso regression technique. It also provides the options to design 19–21 bp siRNA. The effectiveness of this tool is comparable and evaluated as one of the best tools by Matveeva et al. (2007) while comparing with other tools.

### 12.4 RNAi Delivery

In silico siRNA designing is followed by its efficient delivery into an organism of choice for knockdown of the target gene. siRNA delivery strategies employed in fungi mainly comprise of soaking approach using chemically synthesized siRNA or inserting inverted repeat transgenes (IRT) into the desired plasmid using long-hairpin RNA (lhrNA). Table 12.3 lists some of the fungal species in which these strategies have been performed.

#### 12.4.1 Soaking

This technique employs chemically synthesized siRNA(s) which are absorbed by the organism. Briefly, it involves annealing of the siRNA strands, quantification of the siRNA duplex, and soaking of the organism with these double-stranded siRNA(s). This protocol has been followed in protozoan parasite *Entamoeba histolytica* (Solis and Guillén 2008) and schistosomes (Ndewga et al. 2007). In the model

---

**Table 12.2** List of selected siRNA design tools

| S. no | siRNA designing tool         | Website                                                                 |
|------|----------------------------|-------------------------------------------------------------------------|
| 1    | OligoWalk                  | [http://rna.urmc.rochester.edu/cgi-bin/server_exe/oligowalk/oligowalk_form.cgi](http://rna.urmc.rochester.edu/cgi-bin/server_exe/oligowalk/oligowalk_form.cgi) |
| 2    | BLOCK-iTTM RNAi designer   | [https://rnaidesigner.thermofisher.com/rnaiexpress/rnaExpress.jsp](https://rnaidesigner.thermofisher.com/rnaiexpress/rnaExpress.jsp) |
| 3    | RNAi design tool           | [http://eu.idtdna.com/Scitools/Applications/RNAi/RNAi.aspx?source=menu](http://eu.idtdna.com/Scitools/Applications/RNAi/RNAi.aspx?source=menu) |
| 4    | siDESIGN center            | [http://dhharmaon.gelifesciences.com/design-center/](http://dhharmaon.gelifesciences.com/design-center/) |
| 5    | siRNA at whitehead         | [http://sirna.wi.mit.edu/](http://sirna.wi.mit.edu/)                   |
| 6    | TROD                       | [http://www.unige.ch/sciences/biologie/bicel/websoft/RNAi.html](http://www.unige.ch/sciences/biologie/bicel/websoft/RNAi.html) |
| 7    | AsiDesigner                | [http://sysbio.kribb.re.kr:8080/AsiDesigner/menuDesigner.jsf](http://sysbio.kribb.re.kr:8080/AsiDesigner/menuDesigner.jsf) |
| 8    | GenScript’s siRNA design center | [http://www.genscript.com/design_center.html](http://www.genscript.com/design_center.html) |
| 9    | SidiDirect                 | [http://sidirect2.rna.i.j.p](http://sidirect2.rna.i.j.p)/              |
| 10   | Side                       | [http://predictor.nchu.edu.tw/side/about_siDE.php](http://predictor.nchu.edu.tw/side/about_siDE.php) |
| 11   | siVirus                    | [http://sivirus.rna.i.j.p](http://sivirus.rna.i.j.p)/                  |
| 12   | DSIR                       | [http://biodev.extra.cea.fr/DSIR](http://biodev.extra.cea.fr/DSIR)    |
| 13   | SiSearch                   | [http://www.biolabprotocols.com/details/2985/siSearch.html](http://www.biolabprotocols.com/details/2985/siSearch.html) |
| Presence of RNAi machinery in fungi | Gene targeted | Strategy | Inhibition | Refs. |
|----------------------------------|--------------|----------|------------|------|
| **Ascomycetes**                 |              |          |            |      |
| *Aspergillus nidulans*           | *ODC* – fungal ornithine decarboxylase gene | Soaking method | Inhibition of 10%, 26%, 33%, 33% observed with 10 nM, 15 nM, 20 nM, 25 nM siRNA, respectively | Khatri and Rajam (2007) |
|                                  | *Aspergillus nidulans* | Bristle brlAβ – developmental regulatory gene | Inverted repeat of alcA (alcohol dehydrogenase) promoters flanking 498 bp brlAβ upstream | Expression was 3–4 fold less abundant on threonine than that on glucose | Barton and Prade (2008) |
|                                  | *Aspergillus oryzae* | brlA and α-amylase genes | Hairpin RNA cassette of 556 bp brlA, 1656 bp, and 750 bp α-amylase | Decreased signal for brlA gene, reduction in α-amylase activity | Ibrahim et al. (2009) |
| *Aspergillus fumigatus*          | *ALB1/PKSP* – polyketide synthase (melanin biosynthesis pathway) and FKS1 β-(1,3) glucan synthase (cell wall polysaccharide) | 500 bp inverted repeats of ALB1, FKS, and FKS/ALB1 | 29% of pALB1 transformants showed 5% (white colonies) or 24% (light-green colonies) reduction in ALB1 expression, 1% of pFKS1 transformants showed complete RNAi phenotype | Mouyna et al. (2004) |
|                                  | *Aspergillus niger* | xlnR encodes xylanases and cellulases | Inverted repeat of 834 bp of xlnR | 12% transformants showed decreased activities | Oliveira et al. (2008) |
| *Aspergillus parasiticus* and *A. flavus* | *AflR* – transcription factor for expression of aflatoxin biosynthetic genes | Inverted repeat of 670 bp of aflR | aflR IRT transformants expressed verA at levels below the detection limits by N.Blot | McDonald et al. (2005) |
|                                  | *VerA* – gene which is a part of aflatoxin biosynthetic pathway |          |            |      |
| *Fusarium graminearum*           | *Tri6* – transcription factor regulating expression of trichothecene (mycotoxin) biosynthetic genes | Inverted repeat constructs of tri6 ORF with 602 nt in sense and 588 nt in antisense direction | Wheat head blight did not spread to neighboring spikelets | McDonald et al. (2005) |
| Fungi Species | Gene/Construct | Description | Results | References |
|--------------|---------------|-------------|---------|------------|
| *Fusarium verticilloides* (or *F. moniliforme*) | *gus* gene-encoding beta-glucuronidase | Inverted repeat of 627 bp of *gus* gene | Two transformed colonies showed a reduction of 62% and 96% in the *gus* gene expression | Tinoco et al. (2010) |
| *Neurospora crassa* | Albino gene *al-1* involved in carotenoid biosynthesis | Full length *al-1* gene (1971 bp) | 24% of transformants showed albino phenotype | Cogoni and Macino (1997) |
| *Magnaporthe oryzae* (*M. grisea*) | Enhanced GFP (eGFP) | Constructs with sense-sense, antisense-antisense, and sense-antisense orientation of ~700 nt of eGFP | 40 out of 80 IRT transformants emitted 20% fluorescence relative to original GFP | Kadotani et al. (2003) |
| *Schizosaccharomyces pombe* | Enhanced GFP (eGFP) | Inverted repeat of 760 bp of eGFP | Gfp mRNA reduced more than twofold | Sigova et al. (2004) |
| *Histoplasma capsulatum* | AGS1 or α-(1,3)-glucan synthase, cell wall polysaccharide | Inverted repeat of 678 bp of coding sequence of AGS1 | Loss of α-(1,3)-glucan synthase from cell walls | Rappleye et al. (2004) |
| *Cryptococcus neoformans* (JEC21 strain) | CAP59 – capsule synthesis, ADE2 – adenine biosynthesis | 520 nt inverted repeats of CAP59 and ADE2 | ~25% reduction giving dull (CAP59 suppression) and pink (ADE2 suppression) colonies | Liu et al. (2002) |
| *Bipolaris oryzae* | PKS1 – polyketide synthase gene, involved in melanin biosynthesis pathway | Inverted repeats of PKS1 gene fragment (756 bp) | 70% of the transformants showed a melanin-deficient (white color) phenotype | Moriwaki et al. (2007) |
| *Sclerotinia sclerotiorum* | *rgb1* encoding PP2A (type 2A phosphoprotein phosphatase) B regulatory subunit | Inverted repeat of 1.1 kbp of *rgb1* under the control of *A. nidulans* promoter and terminator | *rgb1* suppression inhibited sclerotial maturation and caused reduced pathogenesis | Erental et al. (2007) |
| *Colletotrichum lagenarium* | Enhanced GFP (eGFP) | Construct consisted of 0.72 kb eGFP under the control of *A. nidulans* promoter and terminator | GFP fluorescence reduced to less than 20% of the parent strain | Nakayashiki et al. (2005) |
| *Basidiomycetes* | recA-like recombinase in meiosis – Lim15/Dmc1 | Vector construct with 750 nt antisense and 650 nt sense strand | 23% having meiotic defects, i.e., fruiting body having white cap | Namekawa et al. (2005) |

(continued)
| Presence of RNAi machinery in fungi | Gene targeted | Strategy | Inhibition | Refs. |
|-----------------------------------|--------------|----------|------------|-------|
| **Schizophyllum commune**         | Structural gene – SC15 | 334 nt hairpin construct of SC15 | 80% reduction in aerial hyphae formation and attachment | Jong et al. (2006) |
| **Zygomycetes**                   |              |          |            |       |
| **Mortierella alpina**            | Δ12-desaturase desaturates oleic acid to linoleic acid | 467 nt inverted repeat of Δ12-desaturase | 25–88% decrease in fatty acid production | Takeno et al. (2005) |
| **Mucor circinelloides**          | *carB* – encodes phytoene dehydrogenase enzyme, involved in carotenoid biosynthesis pathway | pMAT647 with 2483 nt of *carB* and pMAT754 with complete cDNA sequence (2334 nt) of *carB* | pMAT647 and pMAT754 gave a silencing frequency of 3.16% and 3.12% with a complete albino phenotype | Nicolás et al. (2003) |
filamentous fungus, *Aspergillus nidulans*, 10 nM, 15 nM, 20 nM, and 25 nM siRNA were used, and a growth inhibition of 10%, 26%, 33%, 33% was observed, respectively, along with a 50% reduction in germ tube length following treatment with 10 nM siRNA-treated samples (Khatri and Rajam 2007; Amarzguioui et al. 2004). The soaking method results in transient expression making it less potent than direct microinjection (Schepers 2005), and therefore its efficiency in targeting the fungal thick cell walls consistently is not much significant.

**12.4.2 Transgenic RNAi**

The soaking method, transient RNAi, has limitations in terms of duration and experimental variability of the RNAi effect. The expression of inverted repeat (IR) transgenes, transgenic RNAi, has been shown to induce stable RNAi in fungi (Liu et al. 2002). However, variability, often, has been observed in the gene silencing effect by dsRNA-producing transgenes depending on the target gene, the type of construct, site of integration, and transgene copy number. An IR is constructed using a target gene sequence, which is incorporated in an organism-specific plasmid. The plasmid containing IR is transformed into the organism that upon transcription forms a hairpin loop which is cleaved by endogenous Dicer to generate siRNA(s). The generated small interfering RNAs (siRNAs) cleave the endogenous mRNA(s) with the help of RISC. Considering that there are several hairpin-expressing RNA systems available for robust RNA silencing using a tissue-specific RNA pol II promoter for tissue-specific expression of dsRNA and that hairpin RNA assures efficient formation of dsRNA, it is the frequently used method for induction of RNA silencing (Paddison and Vogt 2008). One type of IRTs is a long-hairpin RNA (lhRNA) which generally consists of more than 300 bp open reading frame, a spacer of approximately 250–500 oligonucleotides and an inverted repeat of the gene sequence. The IR construct is inserted into the plasmid specific for a particular fungus and is transformed into the respective fungi either by protoplast formation or electroporation. But the transformation/cloning efficiency for long inverted repeats of a cDNA is very low, and the selection process is very time-consuming. The construction of lhRNA(s) is difficult as it involves several rounds of PCR and cloning steps, and moreover, it’s necessary that vectors/plasmids should be available for each species to carry out siRNA delivery. Generally the longer size of spacer helps in the easy cloning of the inverted repeat and improves the efficiency of RNAi. Here, the use of IR constructs containing a short spacer (20–50 bp) in the middle of an inverted repeat improves the cloning efficiency (Yu et al. 2004). Moreover, the presence of introns as a spacer in the constructs also improves their effectiveness and enhances cloning efficiency [48, 49] (Wesley et al. 2001, Kalidas and Smith 2002). Nevertheless, these strategies have been successfully used to trigger silencing in various fungal systems like *Bipolaris oryzae* (Moriwaki et al. 2007) in which an IR was constructed consisting of sense and antisense polyketide synthase gene of 756 bp encoding for melanin production separated by a spacer of cutinase gene intron obtained from a study on
Magnaporthe oryzae (Kadotani et al. 2003), and this yielded melanin-deficient (white) phenotype in 70% transformants. Another study reported only 12% transformants of xlnR encoding xylanases and cellulases of A. niger (Oliveira et al. 2008) showing decreased activities compared to the control strain. The reason

**Fig. 12.2** A schematic representation of the two delivery methods of siRNA is shown. (a) Soaking method which involves soaking of fungi with siRNA. (b) IRT consists of the sense and antisense orientation of the gene separated by a spacer. It is incorporated into plasmid and transformed into fungi. Endogenous Dicer cleaves the hairpin loop which is formed upon transcription of IRT and siRNA(s) is generated. (c) The passenger strand is cleaved, and the guide strand of siRNA enters the RISC where it cleaves the target mRNA.
was attributed to either rearrangement in silencing constructs or apparent decrease in xylanolytic activities or may be absence of “true” co-transformants.

Another prominent IRT successfully used in mammalian systems is the short-hairpin RNA (shRNA) which consists of a 19 bp siRNA sense and antisense sequence separated by a spacer of 9 nucleotides where the siRNA sequence should be 100% homologous to the target mRNA. The shRNA expression vectors available for mammalian systems require RNA polymerase III system as shown in Fig. 12.2.

### 12.5 Validation of Gene Silencing

A preliminary way to investigate the knockdown of a gene and percentage of silencing in fungus is to measure the mycelial growth of fungus by either colony diameter method or mycelial dry weight method (radial growth assays). Blotting techniques, fluorescence imaging, and biochemical assays are the further confirmatory tests which are used to analyze silencing at the RNA and protein levels. A study was carried out by Kadotani et al. (2003) in the blast fungus *M. oryzae* (Holen 2006) in which they investigated RNA silencing using enhanced green fluorescent protein (eGFP). Sense-sense, antisense-antisense, and sense-antisense IRT constructs of eGFP separated by a partial sequence of β-glucuronidase gene as internal spacer were employed. Significant silencing was induced only by sense-antisense IRT construct as detected by the loss of GFP fluorescence using an image analyzer. Several studies have employed Northern blot analysis for studying gene silencing in various fungi (Yamada et al. 2007; Kadotani et al. 2003; Hammond et al. 2007, 2008; Hammond and Keller 2005; Segers et al. 2006; Janus et al. 2007). The captured fluorescence images of plasmids (IRTs) containing fluorescence tags like GFP (Segers et al. 2006; Janus et al. 2007) assist in better understanding of protein localization, confirm the presence of plasmid in the cell, and also facilitate in differentiating the silenced from the non-silenced transformants. Real-time PCR and the reverse transcription PCR (Khatri and Rajam 2007; Oliveira et al. 2008; Janus et al. 2007; Liu et al. 2002) setup are also employed using appropriate gene-specific primers to detect and quantify the gene transcript levels. Liu et al. conducted a study (Liu et al. 2002) on RNA silencing in the pathogenic fungus *Cryptococcus neoformans* where they constructed IRTs on genes related to capsule synthesis and adenine biosynthesis pathway. They observed 25% reduction in the gene expression imparting the transformants with dull and pink colonies, respectively, and silencing analyzed by employing reverse transcription PCR with gene-specific primers and PCR product stained with SYBR Green I nucleic acid gel stain for analysis of DNA-associated fluorescence. Janus et al. investigated a reporter system *DsRed* to identify silencing transformants by cosilencing *DsRed* with the protein isopenicillin N synthase (*pcbC*) involved in cephalosporin C biosynthesis in the filamentous fungus *Acremonium chrysogenum* and employed immunoblotting using a polyclonal antibody against the isopenicillin N synthase to assess the downregulation of the *pcbC* gene (Janus et al. 2007). Biochemical assays can be
performed as well which are specific for the enzyme/protein of interest to evaluate silencing of the target protein by specific siRNA(s). Hammond and Keller in 2005 executed the norsolorinic acid (NOR) analysis by thin-layer chromatography and observed whether the *A. nidulans* *aflR* IRTs can suppress NOR production (Hammond and Keller 2005). Research discoveries in vitro need to be accompanied by establishment of the potentiality of siRNA as a therapeutic. The antifungal drug dosages within the therapeutic window have been tested and determined on animal models, mostly murine models (Ibrahim et al. 2008a, b) for fungal diseases like zygomycosis, aspergillosis, candidiasis, cryptococcosis; but no pharmacological studies have yet been conducted on animal models employing siRNA therapy for fungal infections. Thus, dedicated efforts are needed to assess siRNA therapy for mycoses in various animal models and further investigate in humans through clinical trials.

### 12.6 Conclusion

RNAi has been explored in fungi in the post-genomics era, not only to understand the RNA silencing machinery but also as a tool to treat fungal diseases which cannot be effectively managed by conventional drugs. For instance, the past few decades have seen a rise in the opportunistic invasive fungal infections (mycoses) due to significant increase in the population of immunocompromised patients. The limitations of existing antifungal therapies have provided impetus toward exploring RNAi as a therapeutic option. *N. crassa* was the organism in which the first RNAi gene was discovered which was succeeded by numerous in vitro studies to achieve improved silencing in fungi and promising RNAi as a therapeutic tool. Identification of a potential target gene is necessitated against which siRNA is designed in silico, and recent whole-genome studies in fungi have greatly expedited the novel drug discovery process. Even though RNAi-related research discoveries have made rapid progress from in vitro to in vivo and clinical trials for neurodegenerative diseases and cancer, proper pharmacokinetic parameters of safety and efficacy for RNAi still remain to be answered for mycoses. RNAi as a therapeutic approach is relatively at a nascent stage, and uninterrupted probing should prove useful to drive it as a preferred option for the treatment of mycoses in the long run.

### References

Amarzguioui M, Prydz H (2004) An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun 316(4):1050–1058

Barton L, Prade R (2008) Inducible RNA interference of *brlAβ* in *Aspergillus nidulans*. Eukaryot Cell 7:2004–2007

Bhandari B et al (2009) Antifungal drug resistance – concerns for veterinarians. Veterinary World 2:204–207

Chamilos G, Kontoyiannis D (2005) Update on antifungal drug resistance mechanisms of *Aspergillus fumigatus*. Drug Resist Updat 8:344–358
Cogoni C, Macino G (1997) Isolation of quelling-defective (qde) mutants impaired in posttranscriptional transgene-induced gene silencing in *Neurospora crassa*. Proc Natl Acad Sci U S A 94:10233–10238

Drinnenberg I et al (2009) RNAi in budding yeast. Science 326:544–550

Dujon B et al (2004) Genome evolution in yeasts. Nature 430:35–44

Erental A et al (2007) Type 2A phosphoprotein phosphatase is required for asexual development and pathogenesis of *Sclerotinia sclerotiorum*. MPMI 20:944–954

Fire A et al (1998) Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. Nature 391:806–811

Fulci V, Macino G (2007) Quelling: post-transcriptional gene silencing guided by small RNAs in *Neurospora crassa*. Curr Opin Microbiol 10:199–203

Hammond T, Keller N (2005) RNA silencing in *Aspergillus nidulans* is independent of RNA-dependent RNA polymerases. Genetics 169:607–617

Hammond T et al (2007) *Aspergillus* Mycoviruses are targets and suppressors of RNA silencing. Eukaryot Cell 7:350–357

Hammond T et al (2008) RNA silencing gene truncation in the filamentous fungus *Aspergillus nidulans*. Eukaryot Cell 7:339–349

Holen T (2006) Efficient prediction of siRNAs with siRNArules 1.0: an open-source JAVA approach to siRNA algorithms. RNA 12(9):1620–1625

Ibrahim A et al (2008a) Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 52:1573–1576

Ibrahim A et al (2008b) Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 52:1556–1558

Ibrahim ML et al (2009) Genomic analysis of the basidio sporangium fungus *Rhizopus oryzae* reveals whole-genome duplication. PLoS Genet 5:e1000549

Janus D et al (2007) An efficient fungal RNA-silencing system using the *DsRed* reporter gene. Appl Environ Microbiol 73:962–970

Jinek M, Doudna J (2009) A three-dimensional view of the molecular machinery of RNA interference. Nature 457:405–412

Jong J et al (2006) RNA-mediated gene silencing in monokaryons and dikaryons of *Schizophyllum commune*. Appl Environ Microbiol 72:1267–1269

Kadotani N et al (2003) RNA silencing in the phytopathogenic fungus *Magnaporthe oryzae*. MPMI 16:769–776

Kalidas S, Smith DP (2002) Novel genomic cDNA hybrids produce effective RNA interference in adult Drosophila. Neuron 33(2):177–184

Kawasaki K et al (2003) Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3. Bioorg Med Chem Lett 13:87–91

Khatri M, Rajam M (2007) Targeting polyamines of *Aspergillus nidulans* by siRNA specific to fungal ornithine decarboxylase gene. Med Mycol 45:211–220

Kremery V (1996) Emerging fungal infections in cancer patients. J Hosp Infect 33:109–117

Leuschner P et al (2006) Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO J 25:314–320

Li L et al (2010) RNA interference pathways in filamentous fungi. Cell Mol Life Sci 67:3849–3863

Liu H et al (2002) RNA interference in the pathogenic fungus *Cryptococcus neoformans*. Genetics 160:465–470

Matveeva O et al (2007) Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res 35:e63

McDonald T et al (2005) RNA silencing of mycotoxin production in *Aspergillus* and *Fusarium* species. MPMI 18:539–545

Moriwaki A et al (2007) RNA-mediated gene silencing in the phytopathogenic fungus *Bipolaris oryzae*. FEMS Microbiol Lett 269:85–89
Moussian B (2008) The role of GlcNAc in formation and function of extracellular matrices. Comp Biochem Physiol 149:215–226
Mouyna I et al (2004) Gene silencing with RNA interference in the human pathogenic fungus Aspergillus fumigatus. FEMS Microbiol Lett 237:317–324
Mukherjee P et al (2005) Combination treatment of invasive fungal infections. Clin Microbiol Rev 18:163–194
Münsterkötter M, Mannhaupt G (2008) The posttranscriptional machinery of Ustilago maydis. Fungal Genet Biol 45:S40–S46
Naito Y et al (2006) siVirus: web-based antiviral siRNA design software for highly divergent viral sequences. Nucleic Acids Res 34((Web Server issue)):W448–W450
Nakayashiki H (2005) RNA silencing in fungi: mechanisms and applications. FEBS Lett 579:5950–5957
Nakayashiki H et al (2005) RNA silencing as a tool for exploring gene function in ascomycete fungi. Fungal Genet Biol 42:275–283
Namekawa S et al (2005) Knockdown of LIM15/DMC1 in the mushroom Coprinus cinereus by double-stranded RNA-mediated gene silencing. Microbiology 151:3669–3678
Ndewa D et al (2007) Protocols for gene silencing in schistosomes. Exp Parasitol 117:284–291
Nicolas F et al (2003) Two classes of small antisense RNAs in fungal RNA silencing triggered by non-integrative transgenes. EMBO J 22:3983–3991
Oliveira J et al (2008) Efficient cloning system for construction of gene silencing vectors in Aspergillus niger. Appl Microbiol Biotechnol 80:917–924
Paddison PJ, Vogt PK (2008) RNA interference, Current topics in microbiology and immunology, vol 320. Springer-Verlag, Berlin
Pauw B, Picazo J (2008) Present situation in the treatment of invasive fungal infection. Int J Antimicrob Agents 32:S75–S79
Rappleye C et al (2004) RNA interference in Histoplasma capsulatum demonstrates a role for α-(1,3)-glucan in virulence. Mol Microbiol 53:153–165
Reynolds A et al (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326–330
Ribes J et al (2000) Zygomyces in human disease. Clin Microbiol Rev 13:236–301
Richardson M (1991) Opportunistic and pathogenic fungi. J Antimicrob Chemother 28:1–11
Rogers T (2008) Treatment of zygomycosis: current and new options. J Antimicrob Chemother 61:i35–i39
Romano N, Macino G (1992) Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol Microbiol 6:3343–3353
Ruddon R (2007) Cancer biology, 4th edn. Oxford University Press, New York
Scheipers U (2005) RNA interference in practice: principles, basics, and methods for gene silencing in C. elegans, drosophila, and mammals, 1st edn. Wiley-VCH Verlag GmbH & Co. KGAA, Weinheim
Segers G et al (2006) Hypovirus papain-like protease p29 suppresses RNA silencing in the natural fungal host and in a heterologous plant system. Eukaryot Cell 5:896–904
Sigova A et al (2004) A single Argonaute protein mediates both transcriptional and posttranscriptional silencing in Schizosaccharomyces pombe. Genes Dev 18:2359–2367
Singh S et al (2005) New fungal metabolite geranylgeranyltransferase inhibitors with antifungal activity. Nat Prod Res 19:739–747
Siomi H, Siomi M (2009) On the road to reading the RNA-interference code. Nature 457:396–404
Solis C, Guillén N (2008) Silencing genes by RNA interference in the protozoan parasite Entamoeba histolytica. In: Barik S (ed) RNAi: design and application. Humana Press, Totowa, pp 113–128
Song J et al (2004a) The Candida albicans lanosterol 14-α Demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs. Antimicrob Agents Chemother 48:1136–1144
Song J et al (2004b) Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305:1434–1437
Takeno S et al (2005) Improvement of the fatty acid composition of an oil-producing filamentous fungus, Mortierella alpina 1S-4, through RNA interference with Δ12-desaturase gene expression. Appl Environ Microbiol 71:5124–5128
Tinoco M et al (2010) In vivo trans-specific gene silencing in fungal cells by in planta expression of a double-stranded RNA. BMC Biol 8:27
Tuschl T et al (1999) Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 13:3191–3197
Ui-Tei K et al (2004) Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 32(3):936–948
Vert JP et al (2006) An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 30(7):520
Wapinski I et al (2007) Natural history and evolutionary principles of gene duplication in fungi. Nature 449:54–61
Warnock D, Richardson M (1991) Fungal infection in the compromised patient, 2nd edn. Wiley, Chichester
Wesley SV et al (2001) Construct design for efficient, effective and high-throughput gene silencing in plants. Plant J 27(6):581–590
Yamada O et al (2007) Gene silencing by RNA interference in the Koji Mold Aspergillus oryzae. Biosci Biotechnol Biochem 71:138–144
Yiu S et al (2005) Filtering of ineffective siRNAs and improved siRNA design tool. Bioinformatics 21:144–151
Yu J et al (2004) Transgenic RNAi-mediated reduction of MSY2 in mouse oocytes results in reduced fertility. Dev Biol 268(1):195–206